BioCatalyst

IDE196, Crizotinib, Pembrolizumab, Ipilimumab — catalyst calendar

1 verified catalyst event(s) referencing IDE196, Crizotinib, Pembrolizumab, Ipilimumab, each linked to its official source. Verified as of 2026-10-01.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-01-15
in 4mo
ESTIMATED
 READOUT
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Me
Phase 2/3 · Metastatic Uveal Melanoma
 IDYA IDEAYA Biosciences, Inc. IDE196, Crizotinib, Pembrolizumab, Ipili ClinicalTrials.gov ↗
✓ Source-checked 2026-10-01
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.